Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Apr 18, 2024 12:18pm
236 Views
Post# 35996134

What is the Plan

What is the PlanAndrew Schutte will be loaning "up to $1,000,000 contingent on acquiring all assets of Replicel.

From today's NR:

"The Loan will be secured against all present and after acquired property of RepliCel" .
So in essence this loan will be executed if and when the take-over is completed.

At the moment I see no way that the minority shareholders can stop this which leads me to the question: once the take-over is completed and the loan is in place, What is the plan ?

It would be helpful if the minority share holders knew the plan.  We may even vote to accept this proposal if it looked like we may eventually get some return on our investment.  It puzzles me that we know nothing about how this will move forward and the so called assets will be developed to commercialization as he states.  I still think this is a grab and sell scheme with the minority shareholders receiving a few "crumbs" when all is said and done.

Tell us the plan !


<< Previous
Bullboard Posts
Next >>